CADTH conducted a Health Technology Review on bamlanivimab, a drug authorized (with terms and conditions) by Health Canada to treat adult and pediatric patients 12 years of age or older with mild to moderate COVID-19, who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization. The drug is administered intravenously.

Link to Report

Bamlanivimab in the Treatment of Outpatients With COVID-19: A Critical Appraisal of an Interim Analysis of the BLAZE-1 Trial (Updated January 12, 2021)

Related Work in Progress

Bamlanivimab Implementation Panel

Horizon Scan: Virus-neutralizing monoclonal antibodies against SARS-CoV-2

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.